🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to see the phase 3 RCT of vesicopexy on urinary continence and QOL following RARP, led by Dr. Hooman Djaladat, presented at the Clinical Trials in Progress session! A truly impactful study on a critical topic. #AUA25 Alireza Ghoreifi, MD Farshad Sheybaee Moghaddam USC Urology

It was a great honor to deliver a podium presentation on postoperative ileus following RC + ERAS at #AUA2025. Heartfelt thanks to my mentor Sia Daneshmand, M.D.. Proud to be part of the amazing team at USC Urology!

Honored to present our work on evaluating deprivation indices for radical cystectomy patients at #AUA25! Grateful to have such a wonderful mentor Sia Daneshmand, M.D. and an outstanding team! Anosh Dadabhoy Luis Santos Farshad Sheybaee Moghaddam Domenique Escobar, MD 👩🏽‍⚕️🧜🏽‍♀️ Leilei Xia USC Urology

A lot of talk about patients with borderline renal function (GFR of 40-60 ml/min) that are ? cis-eligible. Here, we present the outcomes of patients from Niagara, showing consistent improvement in EFS and pCR. #AUA2025

Absolutely honored to present our team’s work USC Urology on the impact of insurance on survival after RC in bladder cancer. Grateful to Sia Daneshmand, M.D. for his unwavering support and to Chirag Doshi for his invaluable help throughout!

Photos from our Alumni reception Amer. Urol. Assn. The Venetian Resort Las Vegas #aua25 #alumni #uscurology #lasvegas

Clinical Complete Response to NAC- Ready for Prime Time? urotoday.com/conference-hig… via UroToday.com Matt Galsky Bernie Bochner, MD Ashish M. Kamat, MD, MBBS Zach Klaassen IBCG Bladder Cancer Advocacy Network Petros Grivas SWOG Cancer Research Network Trinity J. Bivalacqua Andrea Necchi Mark Tyson Leslie Ballas Shilpa Gupta Kent Mouw Joshua Meeks

Molecular subtypes in #UrothelialCarcinoma as predictors of response to immunotherapy. #ExpertCommentary Dr. Bishoy M. Faltas WCM Englander Institute for Precision Medicine discusses work from Habib Hamidi, PhD, MPH et al. in Cancer Cell which characterized the molecular determinants of response and resistance to PD-L1

📺 Dr. Sia Daneshmand, M.D. moderates a new roundtable series featuring guest panelists Mark Tyson, Aaron Berger, MD, of Associated Urological Specialists, and Vignesh Packiam, MD discussing the evolving treatment and diagnostic landscape of #NMIBC: buff.ly/UbJobkE ⭐ In part 1, the panelists

Great pleasure discussing our #AUA2025 project led by Sia Daneshmand, M.D. with @vumedi. Huge kudos to our amazing team Chirag Doshi Leilei Xia at USC Urology vumedi.com/video/aua2025-…

Anne Schuckman discusses the Who, When, and How of blue light cystoscopy - a newer technology with the potential to improve bladder cancer management #BladderCancerAwarenessMonth #URO57 open.spotify.com/episode/1n1cNV…

⭐ Drs. Neal Shore and Sia Daneshmand, M.D. discuss a practice-changing research update presented by Dr. Shore at #AUA25 related to #sasanlimab plus #BCG for high-risk non-muscle invasive #bladdercancer: buff.ly/aDkaNk2 👉 Results of the CREST study show that sasanlimab in

This week marked Farshad Sheybaee Moghaddam’s last at USC Urology. From the day I joined USC Urology and throughout last year, he was a true guide to me — and, of course, a beacon of hope in moments of despair. Wishing him all the best as he begins his next chapter at UW Urology !

EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al Read the full update here: buff.ly/DFOK4dt #UroSoMe #MedTwitter #EurUrol

Real-world data improves #NMIBC risk assessment with blue light technology. Sia Daneshmand, M.D. Keck Medicine of USC & Boris Gershman BIDMCUrology join Sam S. Chang MD, MBA Vanderbilt Urology to unveil a new risk model using blue light cystoscopy data. Built from a 1,100-patient registry, it predicts

Honored to join the editorial board of Urologic Oncology as Social Media Editor. Grateful to Dr. Maranchie and Dr. Mark Ball, MD, FACS for their trust. I look forward to helping expand the reach of this esteemed journal across social media platforms. YUO Society of Urologic Oncology Elsevier

So proud to see Nazli Dizman leading efforts for #ASCO25! Stop by the ASCO TECAG Townhall to sort out how to make the most of the meeting!

🧬 Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC): • Most common mutations: TP53, TERT, ARID1A, ERBB2 • ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F) • Only ERBB2 amplifications associated with: